TNFRSF11A and prostate carcinoma: In several malignancies, such as breast, prostate cancer and osteosarcoma, RANK/RANKL expression has been found on both primary and metastatic cells [12–15], as well as in tumor-infiltrating Tregs, known for inhibiting antitumoral immunity [16–17].